I den nyligen publicerade sjätte upplagan av Opticoms årliga branschstudie ligger fokus på framtiden. Här presenteras en aktuell trendspaning där 148 personer från 58 olika företag inom den svenska läkemedelsindustrin har tagit på sig siarhatten och försökt förutspå hur vårdsverige kommer se ut 2025. Kristallkulan visar på både positiv utveckling med minskade regionala skillnader i vårdkvalitet och på negativa förändringar där ojämlikhet i vårdresultat utifrån socioekonomiska parametrar ökar och upptaget av innovativa läkemedel förblir oförändrat lågt, eller till och med försämras ytterligare.
För att läsa nyheter på svenska, klicka här.
In the newly published sixth edition of Opticom’s annual industry study, the focus is on the future.
The report involved the participation of 148 representatives from 58 different companies in the Swedish pharmaceutical industry who have looked in the crystal ball and tried to predict what Swedish healthcare will look like in 2025. The results showed positive developments with reduced regional disparities in quality of care and negative changes where inequality in healthcare results based on socio-economic parameters increases. Lastly, the uptake of innovative medicines will continue to remain low, or decrease even further.
To read the report (in Swedish), click here.
Just before the turn of the millennium, in 1999, the consulting and research company Opticom carried out a survey of how senior representatives of what were at that time the major global pharmaceutical companies saw the future. How well does the companies’ vision coincide with the way things are now, 15 years later?
The report, Prescription for a healthy industry, also formed the basis for a series of articles in Svenska Dagbladet/Näringsliv written by Elisabeth Sandlund. The report was partly based on in-depth interviews with 34 senior executives at what were at that time the 20 largest pharmaceutical companies. Their analysis resulted in three main points:
- There is still a large unsatisfied need for pharmaceuticals. There is no cure for two thirds of all illnesses. The world population is getting older. New research methods are being developed all the time and there will be substantial growth in DTC (direct-to-consumer sales).
- Quick access to market is a key to success. In the face of tougher future competition, companies must launch new innovative products quickly.
- Company mergers slow down companies’ development processes. The top executives questioned the benefits of mergers and wondered whether they were driven by the financial markets and by financial consultants. They were the main beneficiaries of mergers – not the patients.
The winners, predicted the author of the report, will be companies that succeed in achieving a high organic growth rate, companies that sell or outsource in areas outside their own core areas and companies that focus on a small number of therapeutic areas and companies that focus their efforts on their own stores and customers. Companies will benefit from alliances with other companies and research groups, in-licensing, greater investment in research and development and strategic use of information technology.
The losers, on the other hand, would be companies with weak research portfolios but that chose to merge – those companies lose their focus and their rhythm, and therefore their competitiveness…
Article continued in links below
Collaboration is the key to a more holistic view and good health economics and the pharmaceutical industry should be a key player in this. At the same time, it may be high time for the pharmaceutical industry to revise not only its own strategies, but also its self image: To dare to stand for and communicate what the industry actually does and can do in the future. These are some of the results of this year’s industry study conducted by Opticom International Research in collaboration with the Pharma Industry and LIF.
Opticom International Research has since 2010 every year conducted a study in the Swedish pharmaceutical industry in collaboration with Pharma Industry, where people working in the pharmaceutical industry will offer their opinions and predictions for the industry. Since 2012, LIF (the trade association for the research-based pharmaceutical industry in Sweden) has also participated in conducting the study. The aim of the study is to identify the industry’s perception of itself and the perception of its role within the Swedish health care system in order to identify both opportunities and threats for the future.
The pharmaceutical industry is facing both external and internal challenges. The external challenges are a lot about the health care sector’s strong focus on costs and lack of resources, creating a tough market to operate on. The internal challenges are especially about the need to be better at creating a dialogue with the new stakeholders. And LIF, the trade association for the research-based pharmaceutical industry in Sweden, needs to work on strengthening the industry’s reputation. These are some of the main findings of the survey that Opticom conducts each year in collaboration with the Pharma Industry magazine and LIF.
Since 2010, Opticom conducts an annual industry survey in the Swedish pharmaceutical industry in collaboration with Pharma Industry, and since 2012 also with LIF. The study is meant to reflect major industry issues and show how attitudes change over time. The study is designed as a web survey among Pharma Industry’s readers and other relevant people in the industry. This year’s survey was conducted in the spring of 2013.